Adding Chemo to Immunotherapy Provides No Benefit in Older NSCLC Patients
Older adults with PD-L1+ NSCLC may fare better if they receive immunotherapy rather than chemoimmunotherapy, data suggest.
Older adults with PD-L1+ NSCLC may fare better if they receive immunotherapy rather than chemoimmunotherapy, data suggest.
Physician-scientists at Dana-Farber Cancer Institute have received a 5-year, $15 million Program Project Grant from the NCI for research in endometrial cancer
The DAISY Award for nursing provides crucial recognition for nurses and helps combat the heartbreak and compassion fatigue that can come with caring for those…
Two years ago, in one of the first actions of the reignited Biden Cancer Moonshot, President Biden and First Lady Jill Biden announced a call…
Ascites are abnormal pockets of fluid that develop in the abdomen. We spoke to gynecologic oncologist Travis Sims, M.D., to learn more about this late-stage…
Bladder Cancer statistics
A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
Mechanism by which miRNAs regulate hemoglobin switching.Adult-specific let-7 miRNAs inhibit the BCL11A repressor HIC2.
ABC and GCB subtype sinonasal DLBCL are geno- and phenotypically distinct entities, exhibiting a contrasting disease course and prognosis.ABC subtype sinon
Information specialists at NCI’s Cancer Information Service (CIS), NCI’s contact center, are available to help answer your cancer-related questions whether you are a patient, family…
Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.